Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.8633
-0.0226-2.55%
Post-market: 0.88990.0266+3.08%19:37 EST
Volume:1.68M
Turnover:1.42M
Market Cap:93.24M
PE:-3.02
High:0.9076
Open:0.9076
Low:0.8300
Close:0.8859
52wk High:1.51
52wk Low:0.3258
Shares:108.00M
Float Shares:106.00M
Volume Ratio:0.62
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.2881
ROE:-769.06%
ROA:-111.21%
PB:1099.65
PE(LYR):-3.00

Loading ...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)

TIPRANKS
·
Feb 06

Oncolytics Biotech Appoints John McAdory and Yujun Wu to Leadership Team

Reuters
·
Feb 05

Oncolytics receives FDA Fast Track Designation for pelareorep

TIPRANKS
·
Feb 04

FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer

Reuters
·
Feb 04

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L Kras-Mutant Mss Metastatic Colorectal Cancer

THOMSON REUTERS
·
Feb 04

Oncolytics Biotech Inc - to Launch Controlled Study in Second-Line Kras-Mutant Mss Mcrc With Interim Data Expected by End of 2026

THOMSON REUTERS
·
Feb 04

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 22

Oncolytics Biotech Director Bernd R. Seizinger Reports Acquisition of Common Shares

Reuters
·
Jan 21

Oncolytics Biotech Inc. Held Special Shareholder Meeting

Reuters
·
Jan 16

Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Yujun Wu as Head of Biostatistics

Reuters
·
Jan 14

Lake Street Reaffirms Their Buy Rating on Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 13

Oncolytics Biotech Reports Pelareorep Plus Atezolizumab Triples Response Rate in Third-Line Anal Cancer Trial

Reuters
·
Jan 12

Oncolytics Biotech Inc - Four of 14 Third-Line Patients Achieved Objective Responses

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech® Announces Updated Clinical Data From Goblet Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech Inc - Plans Type C Meeting With FDA in Q1 2026

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech Inc - Median Duration of Response About 17 Months

THOMSON REUTERS
·
Jan 12

Oncolytics Biotech Inc - Proposes Change of Incorporation to Nevada

THOMSON REUTERS
·
Jan 09

Oncolytics Biotech Shareholders to Vote on Proposal to Change Incorporation Jurisdiction to Nevada at Upcoming Special Meeting

Reuters
·
Jan 09

Lake Street Remains a Buy on Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 09

BRIEF-Oncolytics Biotech® Provides Update On Intellectual Property Strategy And Patent Filings

Reuters
·
Jan 08